85 Views | 32 Downloads
Paul C. VanVeldhuisen, PhD, The Emmes Company, LLC, 401 N. Washington Street, Suite 700, Rockville, MD 20850; Telephone: 301-251-1161; Fax: 301-251-1355; Email: score2@emmes.com
Andrew Hendrick, MD: Conceptualization, investigation, review and editing Paul C. VanVeldhuisen, PhD: Data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, original draft, review, editing Ingrid U. Scott, MD, MPH: funding acquisition, methodology, project administration, resources, supervision, original draft, review, editing Jacquie King, MS: data curation, formal analysis, validation, original draft, review, editing Barbara A. Blodi, MD: funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, original draft, review, editing Michael S. Ip, MD: methodology, project administration, supervision, original draft, review, editing Rahul N. Khurana, MD: investigation, review and editing Neal L. Oden, PhD: data curation, formal analysis, validation, original draft, review, editing
Andrew Hendrick, MD: No financial disclosures. Paul C. VanVeldhuisen, PhD: No financial disclosures. Ingrid U. Scott, MD, MPH: served on the Data and Safety Monitoring Committee and Safety Review Committee for clinical trials sponsored by Novartis. Jacquie King, MS: No financial disclosures. Barbara A. Blodi, MD: No financial disclosures. Michael S. Ip, MD: consultant for: Boehringer Ingelheim, Thrombogenics, Quark, Omeros, Allergan, Amgen, Astellas, Alimera; honorarium for research support for: Novartis, Genentech, Clearside, Biogen. Rahul N. Khurana, MD: consultant for Allergan, Genentech, and Regeneron; grant support from Allergan, Chengdu Kanghong, Clearside Biomedical, Roche, and Santen. Neal L. Oden, PhD: No financial disclosures.
Supported by the National Eye Institute (National Institutes of Health, Department of Health and Human Services) grants U10EY023529, U10EY023533, and U10EY023521. Support also provided in part by Regeneron, Inc and Allergan, Inc through donation of investigational drug. This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc. to the University of Wisconsin Madison Department of Ophthalmology and Visual Sciences and to the Jules Stein Eye Institute and Doheny Eye Institute, Department of Ophthalmology at the University of California Los Angeles, CA.